PTC299

PTC299 is an oral investigational new drug designed to inhibit the production of vascular endothelial growth factor (VEGF) by targeting the post-transcriptional processes that regulate VEGF synthesis. Over-expression of VEGF plays a key role in multiple diseases including cancer. Read the PTC299 overview to learn more about PTC299.

Advanced Solid Tumors
Recruiting:
PTC is currently enrolling a Phase 1b clinical study of PTC299 in advanced solid tumors. This trial is a three stage study. In Stage 1, up to 18 patients will receive increasingly higher doses of PTC299 in a repeated on-off pattern (4 weeks on drug and 2 weeks off drug) to assess the drug’s safety. In Stage 2, a second group of up to 12 patients will receive PTC299 every day. In Stage 3, a third group of up to 12 patients will receive PTC299 together with the chemotherapy medication, docetaxel (Taxotere®).

Metastatic Breast Cancer
Active not Recruiting:
Phase 1b/2 clinical study of PTC299 in metastatic breast cancer is ongoing at New York University Medical Center. Patients participating in this study take PTC299 by mouth twice a day. Each patient receives the drug in 6-week treatment cycles. Cycles of treatment are repeated for as long as the patient wishes to participate and is potentially benefiting from the drug in the course of the study. This study is testing different doses of PTC299 to further evaluate the activity and safety of the drug. Additionally, the study is monitoring whether PTC299 lowers levels of VEGF in the blood and whether the drug reduces the flow of blood to the tumors and, in turn, decreases tumor size.

Additional information about these PTC299 clinical trials can be found at Clinicaltrials.gov or by contacting Patient and Professional Advocacy at (866) 282-5873, (908) 912-9256 or PatientInfo@ptcbio.com